It is not only a trial design issue but a change in the virus as it has mutated as the trial took so long. . The mutated virus has a different time to symptoms and peak viral load etc. Knowing this as trial progressed they could have considered changing some things of even confirming just what mutation participants had as there is now specific mutation data on viral progression and viral loads available.
Lets be clear if there was a very simple reason SPL IMO would have announced it with some detail rather than the way they did .
In regards to vaccination in the UK it is only elderly who were getting extra doses. In reality everyone was catching covid regularly being reinfected by new mutation
CM IMO needs to come clean and explain why they released the low quality information and inferred poor compliance and explain why that poor compliance happened only under 45 ?
SPL Price at posting:
12.5¢ Sentiment: None Disclosure: Not Held
